FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

•••	 01/	 	· ·			, ,		
				Was	shingt	on,	D.C.	2054

Machinaton	D C	20540	
Nashington,	D.C.	20049	

Vashington,	D.C.	20549	

OMB APPROVAL										
OMB Number:	3235-0362									
Estimated average	burden									
hours per response:										

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
\Box	Form 3 Holdings Reported.

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Form 4	4 Transac	tions R	Reported.	1 1100			ment Company A			'			
1. Name and Address of Reporting Person* <u>CROOKE STANLEY T</u>				2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS]					Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT				3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2020						X Officer (give title Other (specification) Executive Chairman of Board			
(Street) CARLSBAD, CA 92010				4. If Amendmen	t, Date of Orig	ginal Filed (Month	n/Day/Ye	ar)	6. Indi Line) X	vidual or Joint/Gro Form filed by C Form filed by M Person	one Reporting I	Person	
(City)		(Sta		Zip) e I - Non-Deriv a	ative Securitie	es Acquire	ed, Disposed	of, or	Benef	ficially	y Owned		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr.	4. Securities Acquired (A) or Disp Of (D) (Instr. 3, 4 and 5)					6. Ownership Form: Direct	7. Nature of Indirect Beneficial
				(моптирау/теаг)	8)	Amount	(A) or (D)	Price		Issuer's Fiscal Year (Instr. 3 and 4)	(D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock 11/19/2020					11/19/2020	G ⁽¹⁾	31,000 D \$6			0 569,391		I	By trust
			Та	ble II - Derivat (e.g., pı	ive Securities uts, calls, war						Owned		
1 Title of	2	Т	3 Transaction	3A Deemed	1 ₄ 5 N	Jumber 6 Da	ato Evercisable an	d 7 T	itle and	9 1	Price of 9 Number	or of 10	11 Natur

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

Remarks:

/s/Patrick R. O'Neil, attorney-

01/06/2021

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Represents a bona fide gift to a charitable organization.